Susan Makris USEPA, National Center for Environmental Assessment Washington, DC.

Slides:



Advertisements
Similar presentations
The conversion of Saul to St Paul (Michelangelo, 1542) Marcel Leist Doerenkamp-Zbinden Chair For Alternative in vitro Methods, University Konstanz, Konstanz.
Advertisements

Session III: Assessing Cumulative Effects of Endocrine Active Substances 9:15 - 9:30 Introduction” Rick Becker (Session Chair and Panel Moderator) 9:30.
Regulatory Toxicology James Swenberg, D.V.M., Ph.D.
Risk Assessment.
Carcinogen Classification Criteria Patricia Richter Ph.D., DABT Tobacco Products Scientific Advisory Committee June 8, 2010.
Guidelines for Carcinogen Risk Assessment and Supplemental Guidance for Assessing Cancer Risks from Early-Life Exposures March 29, 2005 Hugh A. Barton,
1 Risk assessment: overview and principles –Risk principles –Steps in risk assessment –Risk calculation –Toxicology.
Priority-setting for the Endocrine Disruptor Screening Program: Pesticide Active Ingredients Penelope A. Fenner-Crisp Office of Pesticide Programs U.S.
National Pesticide Program A New Toxicology Testing Paradigm: Meeting Common Needs Steven Bradbury, Director Environmental Fate and Effects Division Office.
CONFERENCE ON “ FOOD ADDITIVES : SAFETY IN USE AND CONSUMER CONCERNS“ JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY NAIROBI, 24 JUNE 2014.
Emissions Transport and Fate Concentrations Exposure Dose Dose-response Relationship Health Risk Schematic overview of a Health Risk Assessment.
Lynne Haber Toxicology Excellence for Risk Assessment Presentation to the CPSC April 8,
Principles of Occupational Toxicology 2 – Types of toxicity
William H. Farland, Ph.D. Acting Deputy Assistant Administrator for Science Office of Research and Development U.S. ENVIRONMENTAL PROTECTION AGENCY Biomarkers:
NSF/ANSI STANDARD 61 FRAMEWORK FOR RISK ASSESSMENTS For use by Toxicology Sub-committee only Please do not copy or distribute.
Module 8: Risk Assessment. 2 Module Objectives  Define the purpose of Superfund risk assessment  Define the four components of the human health risk.
Sources of Uncertainty and Current Practice for Addressing Them: Toxicological Perspective David A. Bussard U.S. Environmental Protection Agency The views.
What Do Toxicologists Do?
Food and Drug Administration Preclinical safety data for “first in human” (FIH) clinical trials in healthy volunteer subjects Oncology Drug Advisory Committee.
June 16-19, USEPA Cancer Guidelines: Mode of Carcinogenic Action 1 ICABR – Impacts of the Bioeconomy on Agricultural Sustainability, the Environment.
Criteria for Screens— Review of the EDSTAC Recommendations Presentation to the EDMVS July 23, 2002.
Preclinical Safety Assessment of Cosmetics & Toiletries Raman Govindarajan, MD, PhD. Regional Director Medical and Scientific Affairs Johnson and Johnson.
Guidance for Industry M4S: The CTD-Safety
EPA’s cancer risk assessment guidelines: General overview Jim Cogliano, Ph.D. United States Environmental Protection Agency* Office of Research and Development.
Characterizing Chemical in Commerce: Using Data on High Production Volume (HPV) Chemicals December 12, 2006 L. Twerdok, Ph.D, DABT NPPTAC Member Report.
Lynn H. Pottenger, PhD, DABT The Dow Chemical Company
Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.
Committee on Carcinogenicity (COC) Approach to Risk Assessment of Genotoxic Carcinogens David H. Phillips* COC Chairman Descriptive vs. Quantitative.
CE Introduction to Environmental Engineering and Science Readings for This Class: Chapter 4 O hio N orthern U niversity Introduction Chemistry,
28/05/12 Questions (Rispondete alle domande che seguono usando il colore rosso per il testo) Tossicologia - Rubbiani Maristella.
Dr. Manfred Wentz Director, Hohenstein Institutes (USA) Head, Oeko-Tex Certification Body (USA) AAFA – Environmental Committee Meeting November 10, 2008.
TRAINING FOR THE HEALTH SECTOR
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Diphenyl Ethers And Developmental Toxicity
TOXICOLOGY Trina Redford, Industrial Hygienist National Naval Medical Center Naval Business Bldg 615, 2 nd Fl. Philadelphia, PA.
Forging Partnerships on Emerging Contaminants November 2, 2005 John Vandenberg Associate Director for Health National Center for Environmental Assessment.
Charge Question 4-1: Please comment on the ecotoxicity studies selected to represent the most sensitive species in each of the risk scenarios (acute aquatic,
Limitations of Current Toxicity Testing for Identifying Early Life Stage Susceptibilities Gary Ginsberg Connecticut Dept of Public Health NE SRA Regional.
Joint Dermatologic and Ophthalmic Drugs & Drug Safety and Risk Management Advisory Committee February 26 & 27, 2004 RISK MANAGEMENT OPTIONS FOR PREGNANCY.
Laboratory toxicology. Toxicological methods In vitro –Cell cultures –Cell-free systems –Mechanistic In vivo (lab animals) –Acute –Subchronic –Chronic.
Of Massachusetts Department ENVIRONMENTAL PROTECTION NE-SRA June 19, 2007 Why are Kids Different? Underlying Biological and Physiological Characteristics.
MAIN TOXICITY TESTING. TESTING STRATEGIES A number of different types of data are used in order to establish the safety of chemical substances for use.
Prof. Dr. Wolfgang Dekant Department of Toxicology University of Würzburg Germany Risk, Hazard, and Innovation.
The McKim Conferences for the Strategic Use of Testing Gitchee Gumee Conference Center Duluth, Minnesota June 27-29, 2006.
Air Toxics Risk Assessment: Traditional versus New Approaches Mark Saperstein BP Product Stewardship Group.
An Overview of the Objectives, Approach, and Components of ComET™ Mr. Paul Price The LifeLine Group All slides and material Copyright protected.
RISK DUE TO AIR POLLUTANTS
The Future of Chemical Toxicity Testing in the U.S.
McKim Conference on Predictive Toxicology The Inn of Lake Superior Duluth, Minnesota September 25-27, 2007 Toxicity Pathways as an Organizing Concept Gilman.
Perspective on the current state-of-knowledge of mode of action as it relates to the dose response assessment of cancer and noncancer toxicity Jennifer.
Toxic effects Acute / chronic Reversible / irreversible Immediate / delayed Idiosyncratic - hypersensitivity Local / systemic Target organs.
Office of Research and Development National Center for Environmental Assessment Human Health Risk Assessment and Information for SRP July 28, 2009 Reeder.
Key Concepts on Health Risk Assessment of Chemical Mixtures.
Acute Toxicity Studies Single dose - rat, mouse (5/sex/dose), dog, monkey (1/sex/dose) 14 day observation In-life observations (body wt., food consumption,
1 Risk Assessment for Air Toxics: The 4 Basic Steps NESCAUM Health Effects Workshop Bordentown, NJ July 30, 2008.
Classification. Hazard Classification The GHS is designed to identify and classify the “hazards” of the substances or mixtures, and to communicate those.
DOSE-RESPONSE ASSESSMENT
From Diagnosis to Conclusion
BIOASSAY OF OESTROGENS
Fundamentals of Industrial Hygiene 6th Edition
Dr. Daniele Wikoff – ToxStrategies Experimental Biology 2017
Susan Makris U.S. EPA, Office of Research and Development
Decision Contexts in a Changing Toxicology Paradigm
The Consortium for Environmental Risk Management, LLC
Case Study: Risk – Risk Comparison n-Propyl Bromide vs
BIOASSAY OF OESTROGENS
Paul Y Hamey Chemicals Regulation Division
EFSA’s Chemical Hazards Database
Human and Animal Testing: What’s Appropriate
VICH GL 54, Studies to evaluate the safety of residues of veterinary drugs in human food: General approach to establish an Acute Reference Dose (ARfD)
Presentation transcript:

Susan Makris USEPA, National Center for Environmental Assessment Washington, DC

Disclosures The views expressed in this presentation are those of the speaker and do not necessarily represent the views or policies of the U.S. EPA. I have no financial or other interests which pose a conflict of interest. No animals have been harmed in the making of this slide presentation.

Definition: Developmental Toxicity Adverse effects on the developing organism that may result from exposure prior to conception (to either parent), during prenatal development, or postnatally to the time of sexual maturation. Adverse developmental effects may be detected at any point in the life span of the organism. The major manifestations of developmental toxicity include: Death Altered growth Structural abnormalities Functional deficits USEPA, 1991, Developmental Toxicity Risk Assessment Guideline OECD, 2008, GD 43: Reproductive Toxicity Testing and Assessment

Prenatal Developmental Toxicity Study OPPTS ; OECD 414  Exposure of dams during major period of fetal organogenesis or during entire duration of gestation  Laparohysterectomy conducted immediately prior to expected day of parturition  Maternal evaluation: o Clinical observations o Body weight, food consumption, and/or water consumption o Necropsy findings  Macroscopic pathology  Ovarian corpora lutea counts  Non-reproductive organ weights are optional o Evaluation of gravid uterus  Gravid uterine weight  Implantation status Counts (live, dead, early and late resorptions, empty implantation sites) Placement in uterine horns  Examination of placental and amniotic fluid  Fetal evaluation: o Fetal sex o External examination o Visceral (soft tissue) examination o Skeletal examination

EPA Data Requirements for Pesticides Acute testing Acute oral, dermal & inhalation Primary eye & dermal irritation Dermal sensitization Acute neurotoxicity Subchronic testing 90-day oral, dermal, &/or inhalation 21/28-day dermal 90-day neurotoxicity Chronic testing Chronic oral Carcinogenicity Developmental toxicity and reproduction Prenatal developmental toxicity (Rodent & NonRodent ) Reproduction and fertility effects Developmental neurotoxicity Mutagenicity testing Bacterial reverse mutation assay In vitro mammalian cell assay In vivo cytogenetics Special testing Metabolism and pharmacokinetics Dermal penetration Immunotoxicity 40 CFR Part 158 (Subpart F – Toxicology) Federal Register, Vol. 72, No. 207, Oct. 26, 2007, pp Why are two species required for developmental toxicity testing? Thalidomide

Purpose of Testing - - Use of Information Broad screening of environmental agents for data that can be used in hazard evaluation and human health risk assessment Basic Components of the Risk Assessment Framework (NRC, 1983, 2009) Reference Value Derivation: RfV = NOAEL (BMD) / UF Uncertainty factors: Human variability Animal-to-human variability LOAEL to NOAEL Duration (subchronic to chronic) Data base Other, e.g., FQPA 10X Hazard Labeling: Classification and Labeling (OECD) Prop 65 (CalEPA) Critical studies for chronic RfV derivation are: Chronic Reproduction Developmental toxicity Examples

Basic Assumptions on Relevance of Developmental Effects to Human Health Risk for Environmental Agents An agent that produces an adverse developmental effect in experimental animals can potentially pose a developmental hazard to humans. All manifestations of developmental toxicity are of concern (i.e., death, structural abnormalities, growth alterations, functional deficits). The types of developmental effects seen in animal studies are not necessarily the same as those that may be produced in humans. The most appropriate and/or most sensitive species is used to estimate human risk. A threshold is assumed for the dose-response curve. These assumptions are: Based upon empirical data on human developmental toxicants (EPA, 1991) Considered to be plausibly conservative and protective of public health

Determining the Most Appropriate Species to Screen Environmental Agents for Developmental Toxicity Information needed for chemical-specific decisions on species selection: Mode/mechanism of action or adverse outcome pathway information Toxicokinetic data (maternal and fetal); internal dose The reality: These data are seldom available for environmental agents. The result: The default position is generally applied for high-exposure substances (i.e., both rodent and non-rodent studies are required). For one or more species

Moving Away from the Default Position The use of validated high through-put, in vitro, and alternative species data Stem cell assays, mouse limb bud assay, whole embryo culture, zebra fish, transcriptomics, in silico models, etc. Predominant current uses: Testing prioritization Weight of evidence discussions Mode of action considerations Unlikely to be a complete replacement for animal testing May help inform future decisions on the approach to testing or the most appropriate species

Learning from Past Experience Retrospective reviews of prenatal developmental toxicity studies conducted in multiple species for the same environmental agents. Important considerations in a cross-species retrospective review: Database used Agents tested Number of studies available Quality/adequacy of studies and reports Comparable protocols used for both rodents and non-rodents Consideration of both developmental and maternal toxicity Common quantitative metric of outcomes (e.g., LOAELs in mg/kg/day) Consideration of qualitative severity of effects

RIVM Analysis of EU Classified Developmental Toxicants Survey of published literature: ~60 classified developmental toxicants chemicals with OECD 414 compliant studies (11 rat, 3 mouse, 7 rabbit, 1 macaque) Minimal Parameter Set Detecting All Compounds: Rorije et al., 2012 Conclusion: At the LOAEL, the most sensitive effects = maternal & fetal weight, fetal survival, skeletal malformations Limitation: No single chemical in this group was studied in both rodents and non-rodents

Rat vs. Rabbit – Environmental Chemicals Conclusions: No overall cross-species difference in sensitivity was seen for detection of developmental NOAELs. Rat and rabbit NOAELs would differ less than a factor of 14 for 95% of the substances. Limitation: NOAELs (not LOAELs) were used as the toxicity metric. Review: 54 chemicals with GHS hazard classification for developmental toxicity, each with both rat and rabbit OECD 414 type studies, derived from peer reviewed North American and European regulatory data sources. Janer et al., 2008

EPA ToxRef DataBase Data Extraction: 383 rat and 368 rabbit prenatal devtox studies on 387 chemicals (mostly pesticides) Conclusions: 53 of 283 chemicals (18.7%) had critical developmental effects that were either specific (i.e., with no maternal toxicity) or sensitive (dLEL<mLEL) in one or the other species. For the majority of studies developmental (and maternal) effects in rats and rabbits were within a 10-fold range. Knudsen et al., 2009

EPA ToxRef DataBase (cont.) Data Extraction: 383 rat and 368 rabbit prenatal devtox studies on 387 chemicals (mostly pesticides) Knudsen et al., 2009 Conclusions (cont.): Species differences in developmental response: In the rat – greater incidence of cleft palate, urogenital and somatic body wall defects, and fetal weight reduction ( ) In the rabbit – greater incidence of neurosensory, cardiovascular, and visceral body wall defects, and of pregnancy loss ( ).

Survey of EPA Integrated Risk Information System (IRIS) Database IRIS Data Set ( >550 assessments (79 w/ Toxicological Review files, 69 of these w/ comparative devtox data) Life Stage Susceptibility analysis: 1)Developmental toxicity LOAEL < maternal toxicity LOAEL, and/or 2)Developmental outcome > severity compared to maternal outcome (e.g., fetal death vs. decreased maternal body weight gain) Cross-Species Sensitivity analysis: 1)Developmental toxicity LOAEL for one species < developmental LOAEL for the other, and/or 2)Developmental outcomes > severity in one species compared to the other (e.g., decreased fetal weight or structural variations vs. death or structural malformations) Conclusion: neither rodents nor non-rodents were more sensitive than the other in detecting developmental toxicity or in identifying life stage susceptibility Limitation: relatively small data set Makris and Iyer, 2012 – SOT poster

Species-Specific DevTox Predictive Model Sipes et al., 2011 Conclusion: while there are cross-species similarities, there are also species differences in the correlation of targets from the HTS in vitro assays with in vivo developmental toxicity. Neither the rat nor the rabbit is predictive of the other. ToxRef DataBase developmental toxicants (subset of 251 rat and 234 rabbit studies): Evaluated the correlation between in vivo toxicity and results of in vitro HTP screening data. Predictive models scored and ranked the chemicals based on in vitro assay activity.

Summary for Environmental Agents Prenatal developmental toxicity studies are important in screening for hazard characterization and risk assessment An evaluation in 2 species (rodent and non-rodent) is required or recommended for high exposure chemicals Sufficient data are seldom available to move away from this default position Several retrospective analyses of rat vs. rabbit studies indicate that the majority of developmental outcomes fall within a ~10-fold dose range, but species-specific responses and outliers are evident More research is needed to provide the predictive tools to depart from the default and conduct information-based testing Replace animals with alternative Reduce the number of animals used Refine the testing Research is needed to accomplish this goal 3 Rs: 4 th R:

Minnie Jessica Current status: For the thousands of untested industrial/environmental chemicals, alternative assays are being utilized to help prioritize testing For chemicals with a high potential for human exposure, a health- protective approach (often utilizing in vivo testing in 2 species) is retained when screening for developmental toxicity Thanks! Friends